🟢 Strong Evidence
Zinc lozenges reduce the duration of the common cold by approximately one-third when taken at sufficient doses, according to a 2017 meta-analysis published in JRSM Open by researcher Harri Hemilä. The effect is substantially larger than most consumers and clinicians realize, and its magnitude depends critically on formulation — specifically, the amount of free ionic zinc available in the lozenge.
Key takeaways
- Zinc lozenges at doses above 75 mg per day of elemental zinc reduce cold duration by 33% on average — approximately 2.3 days shorter than placebo
- The mechanism is well-established: free ionic zinc blocks rhinovirus attachment to nasal cells and inhibits viral replication enzymes
- Formulation matters: not all zinc lozenges deliver the same amount of free ionic zinc, and effectiveness varies by specific product
- This is one of the few over-the-counter remedies with solid randomized controlled trial evidence supporting its use
Study at a Glance
| Source | JRSM Open |
| Study type | Meta-analysis of randomized placebo-controlled trials |
| Trials included | 7 RCTs |
| Total participants | 575 |
| Intervention | Zinc lozenges ≥75 mg/day elemental zinc |
Zinc lozenges shorten common cold by one-third across clinical trials
Duration reduction by daily elemental zinc dose, pooled from 7 randomized placebo-controlled trials (N=575)
Source: Hemilä, JRSM Open, 2017 | Georgian Medical Journal News
How zinc blocks viral entry at the molecular level
Rhinovirus causes approximately 50% of all common colds. To infect a nasal epithelial cell, the virus must first attach to a surface receptor called intercellular adhesion molecule-1 (ICAM-1), which serves as the viral docking site. Without successful attachment, the virus cannot enter the cell or begin replication.
Free ionic zinc (Zn²⁺) disrupts this process through two distinct mechanisms. First, at the cell surface: zinc ions bind directly to both the ICAM-1 receptor and the rhinovirus surface proteins, physically blocking the attachment step. Using X-ray crystallography, Novick and colleagues (1996) identified approximately 360 zinc-binding sites on the surface of rhinovirus-14, demonstrating that the viral particle is essentially coated with potential zinc-binding positions. Second, intracellularly: once viral replication begins inside the cell, zinc inhibits the viral 3C protease, the enzyme responsible for cleaving viral polyproteins into functional components. According to Korant and colleagues, published in Nature (1974), this protease inhibition halts viral replication. The mechanism is not theoretical — it has been elucidated at the atomic and molecular level over decades of biochemical research.
Clinical evidence: 33% reduction in duration from pooled trials
The clinical evidence aligns with the molecular biology. Harri Hemilä’s 2017 meta-analysis, published in JRSM Open, pooled data from 7 randomized placebo-controlled trials involving 575 participants, all of whom used zinc lozenges providing more than 75 mg per day of elemental zinc. The analysis found that the duration of the common cold was reduced by 33% on average. Against a placebo baseline of approximately 7 days, this translates to roughly 2.3 days of symptomatic illness prevented.
Notably, the effect persisted consistently across the dose range tested. Trials using 80 to 92 mg per day of elemental zinc yielded effect sizes comparable to higher-dose regimens, suggesting that the threshold for efficacy lies in the 75–95 mg per day range. This is a substantial clinical effect — one-third reduction in cold duration is larger than most consumers or healthcare providers intuitively expect from an over-the-counter product. For context, this magnitude of effect is comparable to or exceeds that of many prescription antivirals studied for other viral infections in similar-sized trials.
Zinc lozenges at doses above 75 mg per day of elemental zinc reduced the duration of the common cold by 33% on average — approximately 2.3 days shorter than placebo across 7 randomized controlled trials.
— Harri Hemilä, University of Helsinki (JRSM Open, 2017)
Why formulation matters: not all zinc lozenges are created equal
A critical gap exists between published trial data and what consumers purchase at the pharmacy. Clinical efficacy depends on free ionic zinc — the biologically active form that can bind to ICAM-1 and viral proteins. However, not all commercial zinc lozenges deliver high amounts of free ionic zinc. Some formulations use zinc salts that are poorly soluble or are rapidly bound to other compounds in the lozenge, reducing bioavailability. Others use polymer matrices or chelating agents that reduce the concentration of free zinc ions in the mouth and throat.
The trials included in Hemilä’s meta-analysis were conducted with lozenges specifically formulated to deliver high free ionic zinc — often using zinc gluconate or zinc acetate without sorbitol or citrate, which can interfere with zinc availability. Many over-the-counter products marketed for cold relief use different zinc compounds or additives that compromise free ionic zinc delivery, yet are sold at similar or identical prices to evidence-based formulations. Consumers cannot reliably determine free zinc content from package labeling alone, creating a disconnect between the published evidence base and market reality. This is an important consideration for both patients seeking evidence-based self-care and clinicians counseling patients on over-the-counter options.
What this means
Frequently asked questions
Should I take zinc lozenges to prevent a cold, or only after symptoms appear?
The clinical trials included in Hemilä’s meta-analysis tested zinc lozenges initiated within 24 hours of symptom onset, not for prevention. Current evidence supports zinc use as a treatment for active cold symptoms, not as prophylaxis. Starting lozenges after symptom onset appears to be necessary to achieve the 33% duration reduction observed in trials. There is insufficient evidence to recommend routine zinc supplementation as a cold preventive in the general population.
Is 33% reduction in cold duration clinically significant?
Yes, substantially. A reduction from 7 days to 4.7 days represents a meaningful shortening of illness and symptom burden. This effect magnitude is comparable to or exceeds many prescription interventions tested in similar trial designs. For working adults, students, or caregivers, reducing cold duration by 2–3 days is functionally important and justifies the low cost and safety profile of zinc lozenges.
Are there side effects or safety concerns with zinc lozenges?
The trials documented in published meta-analyses reported generally good tolerability. The main adverse effect is local irritation or altered taste, which is generally mild and reversible. However, excessive or prolonged zinc supplementation (beyond the short-term lozenge course during a cold) can interfere with copper absorption and immune function. Zinc lozenges should be used only during active cold illness, not as long-term daily supplements, and patients should follow product-label duration guidance.
As awareness of zinc lozenges’ evidence base grows, both consumers and healthcare systems are reconsidering their role in cold management. The intersection of solid molecular mechanism, robust clinical trial data, low cost, and accessibility makes zinc one of the few over-the-counter remedies warranting serious consideration in evidence-based cold care strategies. Future research might explore whether earlier intervention (within 12 hours of symptom onset) yields even larger benefits, and whether combination strategies with other evidence-based approaches (such as saline irrigation) offer additive effects.
Source: Hemilä, H. Zinc lozenges may shorten the duration of cold: a systematic review. JRSM Open, 2017
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
